Dupilumab efficacy and biomarkers in chronic rhinosinusitis with nasal polyps: Association between dupilumab treatment effect on nasal polyp score and biomarkers of type 2 inflammation in patients with chronic rhinosinusitis with nasal polyps in the phase 3 SINUS-24 and SINUS-52 trials

Claus Bachert, Jonathan Corren, Stella E Lee, Haixin Zhang, Sivan Harel, Danen Cunoosamy, Asif H Khan, Juby A Jacob-Nara, Shahid Siddiqui, Scott Nash, Paul J Rowe, Yamo Deniz, Claus Bachert, Jonathan Corren, Stella E Lee, Haixin Zhang, Sivan Harel, Danen Cunoosamy, Asif H Khan, Juby A Jacob-Nara, Shahid Siddiqui, Scott Nash, Paul J Rowe, Yamo Deniz

No abstract available

Keywords: biomarker; chronic rhinosinusitis; eosinophilic rhinitis and nasal polyposis; paranasal sinus diseases; therapeutics.

Conflict of interest statement

Claus Bachert: ALK, AstraZeneca, GlaxoSmithKline, Mylan, Novartis, Sanofi, and Stallergenes Greer (advisory board member and speakers’ fees). Jonathan Corren: AstraZeneca, Genentech, Inc., Novartis, Regeneron Pharmaceuticals, Inc., and Sanofi (consultancy fees); AstraZeneca and Genentech, Inc. (member of speakers’ bureaus); and Genentech, Inc., Regeneron Pharmaceuticals, Inc., and Sanofi (institutional grant funding). Stella E. Lee: AstraZeneca, GlaxoSmithKline, Regeneron Pharmaceuticals, Inc., and Sanofi (clinical trial funding); and AstraZeneca, Genzyme, GlaxoSmithKline, Novartis, Regeneron Pharmaceuticals, Inc., and Sanofi (advisory board member). Danen Cunoosamy, Asif H. Khan, Juby A. Jacob‐Nara, and Paul J. Rowe: Sanofi (employees, may hold stock and/or stock options). Haixin Zhang, Scott Nash, Sivan Harel, Shahid Siddiqui, and Yamo Deniz: Regeneron Pharmaceuticals, Inc. (employees and shareholders).

Figures

FIGURE 1
FIGURE 1
Scatterplots of the relationship between change from baseline in nasal polyp score (NPS) and change in (A) nasal interleukin (IL)‐5 at week 24 in SINUS‐52 (Controlled Clinical Study of Dupilumab in Patients With Nasal Polyps), and (B) serum total IgE and (C) urinary leukotriene E4 (LTE4) at week 52 in SINUS‐52 (observed values; intent‐to‐treat [ITT] population). n indicates the number of patients with available data for biomarker assessment; and q2w, every 2 weeks.

References

    1. Bachert C, Marple B, Schlosser RJ, et al. Adult chronic rhinosinusitis. Nat Rev Dis Primers. 2020;6:86.
    1. Khan A, Vandeplas G, Huynh TMT, et al. The Global Allergy And Asthma European Network (GALEN) rhinosinusitis cohort: a large European cross‐sectional study of chronic rhinosinusitis patients with and without nasal polyps. Rhinology. 2019;57:32–42.
    1. Hulse KE, Stevens WW, Tan BK, Schleimer RP. Pathogenesis of nasal polyposis. Clin Exp Allergy. 2015;45:328–346.
    1. Stevens WW, Ocampo CJ, Berdnikovs S, et al. Cytokines in chronic rhinosinusitis. Role in eosinophilia and aspirin‐exacerbated respiratory disease. Am J Respir Crit Care Med. 2015;192:682–694.
    1. Schleimer RP. Immunopathogenesis of chronic rhinosinusitis and nasal polyposis. Annu Rev Pathol. 2017;12:331–357.
    1. Macdonald LE, Karow M, Stevens S, et al. Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes. Proc Natl Acad Sci U S A. 2014;111:5147–5152.
    1. Murphy AJ, Macdonald LE, Stevens S, et al. Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice. Proc Natl Acad Sci U S A. 2014;111:5153–5158.
    1. Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS‐24 and LIBERTY NP SINUS‐52): results from two multicentre, randomized, double‐blind, placebo‐controlled, parallel‐group phase 3 trials. Lancet. 2019;394:1638–1650.
    1. Hamilton JD, Harel S, Swanson BN, et al. Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases. Clin Exp Allergy. 2021;51:915–931.
    1. Swinscow TD . Statistics at Square One. 9th ed. In: Campbell MJ. BMJ Publishing Group: 1997.
    1. Wenzel S, Ford L, Pearlman D, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013;368:2455–2466.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit